Abstract Alzheimer's disease (AD), a primary cause of dementia globally, is traditionally
diagnosed via cerebrospinal fluid (CSF) measures and positron emission tomography …

Background Recently developed blood markers for Alzheimer's disease (AD) detection have
high accuracy but usually require ultra-sensitive analytic tools not commonly available in …

Alzheimer's disease (AD), the most prevalent form of dementia, is expected to rise
dramatically in incidence due to the global population aging. Traditional diagnostic …

A growing literature suggests that plasma levels of tau phosphorylated at amino acid 217
(pTau217) performs similarly to cerebrospinal fluid (CSF) biomarkers and PET imaging to …

INTRODUCTION Blood biomarkers have proven useful in Alzheimer's disease (AD)
research. However, little is known about their biological variation (BV), which improves the …

INTRODUCTION Blood biomarkers showed values for predicting future cognitive
impairment. Evidence from the community‐based cohort was limited only in high‐income …

Background Among plasma biomarkers for Alzheimer's disease (AD), pTau181 and
pTau217 are the most promising. However, transition from research to routine clinical use …

Background: Blood biomarkers are proposed as a diagnostic alternative to amyloid PET or
cerebrospinal fluid (CSF) analyses for the diagnosis of Alzheimer's disease (AD). Relatively …

Background An Alzheimer's Association (AA) workgroup published criteria for the diagnosis
and staging of Alzheimer's disease (AD). To date, there have not been empirical …

The revised biomarker framework for diagnosis and staging of Alzheimer's disease (AD)
relies on amyloid beta (Aβ) and tau pathologies as core markers, and markers for adjacent …